Definium Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Definium Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Definium Therapeutics Inc DFTX.OQ reported a quarterly adjusted loss of $1.44 per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -50 cents. The mean expectation of fifteen analysts for the quarter was for a loss of 55 cents per share. Wall Street expected results to range from -72 cents to -44 cents per share.
Reported revenue was zero; analysts expected zero.
Definium Therapeutics Inc's reported EPS for the quarter was a loss of $1.44.
The company reported a quarterly loss of $158.99 million.
Definium Therapeutics Inc shares had fallen by 5.6% this quarter and gained 231.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 3.8% in the last three months.
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
Wall Street's median 12-month price target for Definium Therapeutics Inc is $59.00, about 24.8% above its last closing price of $44.39
This summary was machine generated from LSEG data August 6 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.55 | -1.44 | Missed |
Mar. 31 2026 | -0.49 | -0.71 | Missed |
Dec. 31 2025 | -0.49 | -0.50 | Missed |
Sep. 30 2025 | -0.50 | -0.78 | Missed |